Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-1: Psilocybin and Subjective Experience
NCT06768944Phase 2Recruiting
- Sponsor
- University of Calgary
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin (4 arms), sponsored by University of Calgary. Primary endpoint: Positive effects at 1 month. Started May 2026; status: recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT06768944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768944.